Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
Trial ID or NCT#
Status
NOT RECRUITING
Purpose
The purpose of this study is to assess long-term side effects from subjects who receive an Adicet Bio γδ CAR T cell product. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years from the first administration of Adicet Bio allogeneic γδ CAR T cell product, subjects will be assessed for long-term safety and survival through collection of data that include safety, efficacy, pharmacokinetics and immunogenicity.
Official Title
Long-term Follow-up Protocol for Subjects Treated With Adicet Allogeneic Gamma Delta (γδ) CAR T Cell Investigational Products
Eligibility Criteria
- - All patients who received any Adicet allogeneic CAR T investigational product and have either completed the core treatment protocol or have discontinued early - All patients who are willing and able to adhere to the study visit schedule and other protocol requirements. - Capable of giving signed informed consent which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and protocol
- - There are no specific exclusion criteria for this study
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
David Miklos, MD
650-723-0822
View on ClinicalTrials.gov
